, England’s largest NHS trust, has recruited its final participant to a leading COVID-19 vaccine trial. The Phase 3 study is testing the safety and effectiveness of a new two-dose vaccine regimen, versus a placebo, in preventing moderate to severe/critical coronavirus disease. The vaccine candidate has been developed by The Janssen Pharmaceutical Companies of Johnson & Johnson, as researchers around the world continue to work to secure a range of vaccines and treatments to help tackle coronavirus. Dr Tim Felton, an Honorary Consultant at MFT’s Wythenshawe Hospital, is the Trust’s Clinical Lead for all COVID-19 research, as well as the Principal Investigator at MFT for the Janssen Phase 3 study.